Article info
PDFSystemic lupus erythematosus
Biological impact of iberdomide in patients with active systemic lupus erythematosus
- Correspondence to Dr Peter E Lipsky, RILITE Foundation, Charlottesville, USA; peterlipsky{at}comcast.net
Citation
Biological impact of iberdomide in patients with active systemic lupus erythematosus
Publication history
- Received January 21, 2022
- Accepted April 10, 2022
- First published April 27, 2022.
Online issue publication
July 12, 2022
Article Versions
- Previous version (27 April 2022).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.